News releases Year None2023202220212019 May 30, 2023 Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs PDF Version May 24, 2023 Pyxis Oncology to Acquire Apexigen PDF Version May 11, 2023 Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update PDF Version Mar 31, 2023 Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version Mar 22, 2023 Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update PDF Version Mar 16, 2023 Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors PDF Version Feb 13, 2023 Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference PDF Version
Year None2023202220212019 May 30, 2023 Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs PDF Version May 24, 2023 Pyxis Oncology to Acquire Apexigen PDF Version May 11, 2023 Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update PDF Version Mar 31, 2023 Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version Mar 22, 2023 Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update PDF Version Mar 16, 2023 Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors PDF Version Feb 13, 2023 Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference PDF Version
